Lilly will get exclusive, global rights to research, develop, manufacture and commercialise these therapies with Camurus’ FluidCrystal technology. The agreement includes up to four drug compounds from Lilly.
Glepaglutide is intended for administering two times a week for SBS. The application is based on results from the pivotal Phase III clinical trial EASE-1, supported by interim
The company’s wholly owned subsidiary T-mab developed the drug. It is Mabwell’s first commercialised innovative drug, and the first introduced granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting
Previously known as AR-15512, Tryptyr is a transient receptor potential melastatin 8 (TRPM8) receptor agonist that stimulates corneal sensory nerves to increase production of natural tears rapidly. It
This partnership will advance the receptor-based targeting molecule into clinical development. Under the agreement terms, Archeus Technologies will be responsible for leading the Phase I clinical development of
Radiprodil is being investigated for its potential in treating rare genetic epilepsies and neurodevelopmental disorders (NDDs). It is a targeted, selective and negative allosteric modulator of the GluN2B
HLX22 is the first anti-HER2 targeted treatment to receive ODD from both the US Food and Drug Administration (FDA) in March 2025 and from the EU. An international
This key plasma protein of Shilpa is utilised across different medical applications. It is developed using a non-human expression system that ensures scalability, high safety and virus-free production.
This decision marks the injection as the first and only approved continuous delivery treatment by the FDA capable of maintaining vision in DR patients, with a refill required
The funding will enable the company to deliver critical clinical readouts for its core medicine pipeline. Investor M42 spearheaded the funding round, with continued support from current investors.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.